Hayley Virgil is a senior editor with CancerNetwork. When she isn't traveling to conferences and championing health equity in the oncology space, she can be found hiking, foraging wild plants, gardening, sewing ballgowns, practicing embroidery, or playing video games.
Patients With Metastatic Pancreatic Cancer Who Reported Higher Daily Step Counts Had Greater QoL on SM-88January 18th 2021
Overall self-reported quality of life in patients with metastatic pancreatic cancer was correlated with their mean daily step count during the first 2 weeks of treatment on SM-88.
Atezolizumab, Chemo Combo Improves Outcomes Without Adding Treatment Burden in Early TNBCDecember 11th 2020
Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.
PreciseDx Accurately Classifies Low-Risk Recurrence Scores in Breast CancerDecember 10th 2020
PreciseDx, an artificial intelligence–digital breast cancer risk discrimination platform, was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.
PORT Not Recommended as Standard of Care for Completely Resected Stage IIIAN2 NSCLCSeptember 26th 2020
Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.
Adding Nivolumab to Chemo Improves PFS, Elicits Higher ORR in Gastric/GEJ CancersSeptember 24th 2020
The addition of nivolumab (Opdivo) to chemotherapy resulted in a statistically significant improvement in PFS and evoked higher ORRs in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.